Pricing Log in Create free account

Fulcrum Therapeutics, Inc. (FULC) vs Palisade Bio, Inc. (PALI)

Fulcrum Therapeutics, Inc. and Palisade Bio, Inc. are both Biotechnology companies. Fulcrum Therapeutics, Inc. and Palisade Bio, Inc. are of similar size ($280.0M and $268.4M). Fulcrum Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against 1,939.8%. Fulcrum Therapeutics, Inc. has the higher net margin (0.00% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Fulcrum Therapeutics, Inc. leads on 11 and Palisade Bio, Inc. on 4.

Valuation

Metric FULC PALI Biotechnology median
P/E n/m 2.18 8.50
P/S 3.37 394.77 9.71
P/B 0.90 2.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.43 n/m 0.64
EV/Sales (0.49) 229.61 9.21
Earnings yield (33.15%) 45.93% (33.15%)
Free cash flow yield (23.60%) (6.11%) (25.50%)

Profitability

Metric FULC PALI Biotechnology median
Gross margin 100.00% 95.63% 65.16%
Operating margin 0.00% (4,681.99%) 0.00%
Net margin 0.00% (4,230.60%) 0.00%
Free cash flow margin 0.00% (2,409.27%) 0.00%
Return on equity (32.38%) (51.37%) (56.36%)
Return on assets (30.75%) (47.68%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric FULC PALI Biotechnology median
Revenue growth (TTM) 1,939.80% 5,492.59% 6.02%
EPS growth (last fiscal year) (637.50%) 97.06% 30.26%
Revenue growth, 5-year CAGR — 72.86% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FULC PALI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.35 24.26 4.72
Net debt to EBITDA 4.23 7.37 0.96

Dividend

Metric FULC PALI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FULC PALI Biotechnology median
Market cap 280.01m 268.38m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack